SCHEMBL1303789

SCHEMBL1303789

CCc1cnc(CCNC(=O)Nc2cn3cc(Br)ccc3n2)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 3/20 0.44
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PIK3CA P42336 5/20 0.36
ROCK2 O75116 1/20 0.35
METTL3 Q86U44 1/20 0.35
PIK3CD O00329 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
PIK3C3 Q8NEB9 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
CCNB2 O95067 1/20 0.32
CCNE2 O96020 1/20 0.32
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CCNB1 P14635 1/20 0.32
CCND1 P24385 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
CCNB3 Q8WWL7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3716984 0.86 MAP3K5 (0.51) MAP3K5NPC1RAB9APIK3CAROCK2
SCHEMBL3146588 0.79 PIK3CA (0.64) PIK3CAPIK3CDPIK3CBPIK3CGPIK3C3
SCHEMBL1303573 0.77 MAP3K5 (0.45) MAP3K5NPC1RAB9APIK3CAROCK2
SCHEMBL1303590 0.74 MAP3K5 (0.47) MAP3K5NPC1RAB9APIK3CAROCK2
SCHEMBL1302857 0.74 MAP3K5 (0.44) MAP3K5NPC1RAB9APIK3CAROCK2
SCHEMBL1302670 0.74 MAP3K5 (0.44) MAP3K5NPC1RAB9APIK3CAROCK2
SCHEMBL1303903 0.73 MAP3K5 (0.46) MAP3K5NPC1RAB9APIK3CAROCK2
SCHEMBL3709433 0.73 MAP3K5 (0.53) MAP3K5NPC1RAB9AROCK2CDK2
SCHEMBL1303492 0.72 MAP3K5 (0.55) MAP3K5NPC1RAB9APIK3CAROCK2
SCHEMBL13853450 0.71 CCNB2 (0.41) CCNB2CCNE2CDK1CDK4CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053574-B2 Organic compounds NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100197682-A1 Organic Compounds NOVARTIS AG 2010-08-05 US disclosed
EP-2178868-A1 BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Novartis Ag (CH) 2010-04-28 EP disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 US disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 US disclosed
CN-101384586-A PI-3 kinase inhibitors and methods of use thereof NOVARTIS AG (CH) 2009-03-11 CN disclosed
WO-2009010530-A1 BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS NOVARTIS AG (CH) 2009-01-22 WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE PIK3CA, PIK3CD, PIK3CB MAP3K5 192/4885NPC1 1650/4885RAB9A 1046/4885
US-20100197682-A1 Organic Compounds PIK3CA, PI4KA, PI4KB MAP3K5 160/4885NPC1 1077/4885RAB9A 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.